| Relapsed patients (n = 21) | CD19- relapse (n = 13) | CD19 + relapse (n = 8) |
|---|---|---|
| Female | 7 | 2 |
| Age at infusion (years) | 7 (1-24) | 9 (5-18) |
| Prior EMD | 5 | 5 |
| Prior HSCT/Inotuzumab/Blinatumomab | 8/1/1 | 6/0/0 |
| TREATMENT AND OUTCOME AFTER RELAPSE | ||
| Inotuzumab/Blinatumomab/Reinfusion | 6ª/0/0 | 0/2b/3c |
| Chemotherapy/Palliative | 3d/1 | 2e/1 |
| HSCT after CR | 4 (3 alive in CR) | 3 (alive in CR) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.